Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90

Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease

(2016) Liza Shrestha et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation

(2015) Jifeng Wang et al.   CANCER LETTERS

The Heat Shock Protein 90 Inhibitor, (-)-Epigallocatechin Gallate, Has Anticancer Activity in a Novel Human Prostate Cancer Progression Model

(2015) M. A. Moses et al.   Cancer Prevention Research

17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition

(2015) ZHIYUAN LIN et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model

(2015) Won Jai Lee et al.   PLASTIC AND RECONSTRUCTIVE SURGERY

Targeting HSF1 sensitizes cancer cells to HSP90 inhibition

(2015) Yaoyu Chen et al.   Oncotarget

Stabilization of integrin-linked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response

(2013) Korana Radovanac et al.   EMBO JOURNAL

Hsp90, an unlikely ally in the war on cancer

(2013) Jared J. Barrott et al.   FEBS Journal

Cell mates: paracrine and stromal targets for prostate cancer therapy

(2013) Pavel Sluka et al.   Nature Reviews Urology

Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: Implications for the prostate tumor microenvironment

(2013) JE Bohonowych et al.   PROSTATE

HSP90 Inhibitors: Current Development and Potential in Cancer Therapy

(2013) Katerina Sidera et al.   Recent Patents on Anti-Cancer Drug Discovery

Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition

(2012) Mikko Taipale et al.   CELL

Reduction of pro-tumorigenic activity of human prostate cancer-associated fibroblasts using Dlk1 or SCUBE1

(2012) B. Orr et al.   Disease Models & Mechanisms

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

(2012) SUQIN HE et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Secreted Hsp90 Is a Novel Regulator of the Epithelial to Mesenchymal Transition (EMT) in Prostate Cancer

(2012) Michael W. Hance et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium

(2012) Freddie L. Pruitt et al.   PROSTATE

Novel C-Terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents

(2011) Stephanie M. Cohen et al.   ANNALS OF SURGICAL ONCOLOGY

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells

(2011) Jeffery D Eskew et al.   BMC CANCER

Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth

(2011) Michael S. Samuel et al.   CANCER CELL

Role for Stromal Heterogeneity in Prostate Tumorigenesis

(2011) M. A. Kiskowski et al.   CANCER RESEARCH

Altered TGF-β Signaling in a Subpopulation of Human Stromal Cells Promotes Prostatic Carcinogenesis

(2011) Omar E. Franco et al.   CANCER RESEARCH

The specificities of small molecule inhibitors of the TGFß and BMP pathways

(2011) Janis Vogt et al.   CELLULAR SIGNALLING

A Triazine Compound S06 Inhibits Proinvasive Crosstalk between Carcinoma Cells and Stromal Fibroblasts via Binding to Heat Shock Protein 90

(2011) Da-Woon Jung et al.   CHEMISTRY & BIOLOGY

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

(2011) Simon Pacey et al.   CLINICAL CANCER RESEARCH

The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors

(2011) G. Floris et al.   MOLECULAR CANCER THERAPEUTICS

Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance

(2011) Katherine J. O'Malley et al.   PROSTATE

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer

(2011) William K. Oh et al.   UROLOGY

HSP90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion

(2010) Aftab Taiyab et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer

(2010) B. Wegiel et al.   CURRENT CANCER DRUG TARGETS

LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells

(2010) Rebecca W. Scott et al.   JOURNAL OF CELL BIOLOGY

The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine

(2010) Hayley C. Whitaker et al.   PLoS One

Clonal Mutations in the Cancer-Associated Fibroblasts: The Case against Genetic Coevolution

(2009) I. Campbell et al.   CANCER RESEARCH

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL

Cancer associated fibroblasts in cancer pathogenesis

(2009) Omar E. Franco et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY